Ticker

Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director owned 32,944,484 shares of the

Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 532,131 shares, an increase of 65.0% from the March 15th total of 322,575 shares. Currently, 1.2% of the shares of the company are

Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Vivani Medical and

Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.